Published: Sep 11, 2025, 10:51 IST | Updated: Sep 11, 2025, 10:51 IST
The Trump administration is considering an executive order that could severely limit the U.S. pharmaceutical industry’s ties to China. It could potentially cut off access to a growing pipeline of Chinese-invented experimental drugs.